AUROPHARMA
Aurobindo Pharma Limited
Each stock's 10,000-path forecast, rendered as light.
Aurobindo Pharma Limited (AUROPHARMA) Stock Analysis & Case Study
Is AUROPHARMA a good buy? The data-driven verdict.
Aurobindo Pharma Limited (AUROPHARMA) trades at ₹1,658,on the numbers it tread carefully, a Downstox Snapshot Score of 39/100.
On the numbers, Aurobindo Pharma Limited (AUROPHARMA) tread carefully, a Downstox Snapshot Score of 39/100, weighing premium at 25.5× earnings, ROE of 10.1%, a 60% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
AUROPHARMA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How AUROPHARMA ranks against the 2,373 companies in our screener
- AUROPHARMA's market cap of 96,297 Cr ranks in the top 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AUROPHARMA's book value of ₹652 ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AUROPHARMA's promoter holding of 51.9% ranks in the 35th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AUROPHARMA's 3-year profit (PAT) growth of 23.0% ranks in the 60th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AUROPHARMA's 3-year revenue growth of 11.0% ranks in the 53rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AUROPHARMA's debt-to-equity ratio of 0.21x is lower than 61% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is AUROPHARMA overvalued? AUROPHARMA P/E vs its Pharma
AUROPHARMA's P/E of 25.5× sits below the Pharma peer median of 33.0×, so on earnings it screens cheaper than peers, while its 0.24% dividend yield is below the peer median of 0.68%.
AUROPHARMA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of AUROPHARMA history (8%/yr drift, 28%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| AUROPHARMA 2027 | ₹1,259 | ₹1,770 | ₹2,487 | +7% |
| AUROPHARMA 2028 | ₹1,152 | ₹1,889 | ₹3,096 | +14% |
| AUROPHARMA 2029 | ₹1,099 | ₹2,016 | ₹3,698 | +22% |
| AUROPHARMA 2030 | ₹1,057 | ₹2,151 | ₹4,380 | +30% |
| AUROPHARMA 2031 | ₹1,051 | ₹2,296 | ₹5,019 | +38% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability AUROPHARMA goes up, or doubles?
The bull case for AUROPHARMA
- Aurobindo Pharma Limited is part of the nifty100 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹3,698.
The bear case & risks
- AUROPHARMA's P/E of 25.5x is lower than 52% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AUROPHARMA's return on equity of 10.1% ranks in the 51st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,099.
AUROPHARMA volatility & expected range, how bumpy is the ride?
Over the last 9.8 years AUROPHARMA compounded at 8%/year with annualized volatility of 28%. That volatility implies a 1-year 80% range of ₹1,259-₹2,487, the honest backbone behind any single price target.
AUROPHARMA price forecast, the full 60-month probability fan
AUROPHARMA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds AUROPHARMA hits common targets within the simulated horizon?
Full multi-horizon detail on the AUROPHARMA price target & forecast page.
AUROPHARMA Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. AUROPHARMA scores 6/8, mixed financial health.
AUROPHARMA MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy AUROPHARMA with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 24.87% | 4.0× |
| Zerodha | 24.30% | 4.1× |
| Groww | 24.16% | 4.1× |
| Dhan | 23.00% | 4.3× |
| Kotak Neo | 21.51% | 4.6× |
| Paytm MoneyCHEAPEST | 21.43% | 4.7× |
| Pocketful | 28.46% | 3.5× |
| Anand Rathi | 28.52% | 3.5× |
| Bajaj Broking | 24.00% | 4.2× |
| Share India | 28.37% | 3.5× |
Compare every broker on the AUROPHARMA MTF page.
AUROPHARMA vs peers,Pharma comparison
| Stock | P/E | Div yield | Market cap |
|---|---|---|---|
| AUROPHARMA (this stock) | 25.5× | 0.24% | ₹96,297 Cr |
| SUNPHARMA | 36.9× | 0.82% | ₹4.67L Cr |
| DIVISLAB | 73.7× | 0.36% | ₹2.20L Cr |
| DRREDDY | 30.4× | 0.68% | ₹97,824 Cr |
| CIPLA | 33.0× | 0.89% | ₹1.18L Cr |
| LUPIN | 18.2× | 0.76% | ₹1.08L Cr |
| BIOCON | 95.5× | 0.12% | ₹69,482 Cr |
Fundamentals from Screener.in, as of 9 Aug 2026
About Aurobindo Pharma Limited: sector, index & market-cap context
Aurobindo Pharma Limited (AUROPHARMA) is a mid-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 500 index, with a market capitalisation of ₹96,297 Cr. See more stocks on our screener.
How the AUROPHARMA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Aurobindo Pharma Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
AUROPHARMA analysis, FAQs
Is Aurobindo Pharma Limited (AUROPHARMA) a good buy?
On the numbers, Aurobindo Pharma Limited (AUROPHARMA) tread carefully, a Downstox Snapshot Score of 39/100, weighing premium at 25.5× earnings, ROE of 10.1%, a 60% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is AUROPHARMA overvalued or undervalued?
AUROPHARMA trades at 25.5× earnings versus a peer median of 33.0×, so it screens cheaper than its Pharma peers.
What is the AUROPHARMA share price target for 2031?
AUROPHARMA's probability-weighted 2031 median target is ₹2,296, with an 80% range of ₹1,051-₹5,019 (10,000-path Monte-Carlo).
What is the probability AUROPHARMA doubles in 5 years?
The modelled probability of AUROPHARMA reaching ₹3,316 (2×) within 5 years is 27%.
What is the bull case for AUROPHARMA?
Aurobindo Pharma Limited is part of the nifty100 universe with live, tracked fundamentals on Downstox.
What are the risks in AUROPHARMA?
AUROPHARMA's P/E of 25.5x is lower than 52% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. AUROPHARMA's return on equity of 10.1% ranks in the 51st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.